News | February 12, 2015

Ablative Solutions Developing Denervation System to Treat Hypertension

Percutaneous catheter designed to deliver diagnostic and therapeutic agents through vessel walls to the outer region of arteries

Renal denervation, hypertension, Peregrine System

Image courtesy of Ablative Solutions

February 12, 2015 — Ablative Solutions Inc. announced the addition of Michael Weber, M.D., FACP, FACC, FAHA, to its Scientific Advisory Board. Weber is a distinguished expert in the areas of hypertension and preventive cardiology. He is currently Professor of Medicine at SUNY Downstate College of Medicine in Brooklyn, New York. He is the editor-in-chief of The Journal of Clinical Hypertension. Weber was one of the founders of The American Society of Hypertension and has served as its President.

Ablative Solutions has developed a patented device, the Peregrine System, which is a percutaneous catheter designed to deliver diagnostic and therapeutic agents through vessel walls to the outer region of arteries. The Peregrine System has been cleared by the U.S. Food and Drug Administration (FDA) for the infusion of diagnostic and therapeutic agents into the perivascular area.

Ablative Solutions is currently investigating the use of the Peregrine System in a clinical study in Europe intended to secure a CE Mark. The System is being evaluated for renal denervation, providing a treatment that delivers therapy directly to the nerves that run along the perimeter of the renal artery. The interruption of these nerve pathways may have therapeutic implications for hypertension, metabolic syndrome, congestive heart failure and obesity. The system is not currently cleared or approved in the United States for renal denervation, or for the treatment of hypertension, metabolic syndrome, congestive heart failure or obesity.

For more information: www.ablativesolutions.com

Related Content

BackBeat Cardiac Neuromodulation Therapy Shows Immediate, Substantial Blood Pressure Reduction
News | Hypertension | June 04, 2019
Orchestra BioMed Inc. announced the presentation of two-year clinical data from the European Moderato I study of...
St. Bartholomew's Hospital Initiates CALM-2 Hypertension Trial
News | Hypertension | February 20, 2019
California-based Vascular Dynamics Inc. (VDI) is sponsoring a new clinical trial, called CALM-2 (Controlling And...
Research Sheds Light on Blood Pressure Drug Function
News | Hypertension | January 31, 2019
Researchers have mapped the active-state structure of the angiotensin II type 1 receptor, the target of widely...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Hypertension | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Barbershop Intervention Continues to Lower Blood Pressure at One Year
News | Hypertension | December 27, 2018
African-American men participating in a blood pressure reduction program implemented in barbershops continued to have...
Analytics 4 Life and Actelion to Develop New Diagnostics for Pulmonary Hypertension
News | Hypertension | December 14, 2018
Digital health company Analytics 4 Life and Actelion Pharmaceuticals Ltd. announced a collaborative agreement to...
Hypertensive Crisis Five Times More Likely Among Blacks, according to a late-breaking study at AHA 2018. #AHA #AHA18 #AHA2018
News | Hypertension | November 13, 2018
Black adults experience dangerous spikes in high blood pressure, called a hypertensive crisis, at a rate that is five...
Home Monitoring Confirms Clinic Diagnosis of High Blood Pressure
News | Hypertension | October 29, 2018
Blood pressure readings of 130/80 millimeters of mercury (mmHg) or higher taken at home can be used to diagnose...
 Pulmonary artery denervation for CpcPH from the PADN-5 trial. #TCT2017

A series of procedural images of a pulmonary artery denervation for CpcPH from the PADN-5 trial.

News | Hypertension | October 04, 2018
October 4, 2018 — Pulmonary artery denervation (PADN) is associated with significant improvements in hemodynamic and
Overlay Init